 Connection
Jason Glanz to Opiate Substitution Treatment
This is a "connection" page, showing publications Jason Glanz has written about Opiate Substitution Treatment.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.185 |
|
|
|
-
Nguyen AP, Binswanger IA, Narwaney KJ, Goodrich G, Christine PJ, Campbell CI, Xu S, Loree AM, Glanz JM. Health Plan Disenrollment and Mortality After Initiation of Medications for Opioid Use Disorder. JAMA Psychiatry. 2026 May 01; 83(5):491-498.
Score: 0.801
-
Guan X, Jurecka C, Padmanabhan P, Yamkovoy K, Christine PJ, Binswanger IA, Glanz JM, Kline DM, Barocas JA. Impact of increased criminal penalties for fentanyl possession on initiation and retention on medications for opioid use disorder in Colorado. Int J Drug Policy. 2025 12; 146:105037.
Score: 0.193
-
Glanz JM, Binswanger IA, Clarke CL, Nguyen AP, Ford MA, Ray GT, Xu S, Hechter RC, Yarborough BJH, Roblin DW, Ahmedani B, Boscarino JA, Andrade SE, Rosa CL, Campbell CI. The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment. Addiction. 2023 01; 118(1):97-107.
Score: 0.154
-
Nguyen AP, Glanz JM, Shoup JA, Campbell CI, Clarke CL, Ford MA, Binswanger IA. Mortality Among Patients Prescribed Buprenorphine for Opioid Use Disorder After Disenrollment from an Insurance Plan and Healthcare System. J Gen Intern Med. 2022 08; 37(11):2882-2884.
Score: 0.037
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|